MedTrace Logo

Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC

NCT06643793 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-01-28

No results posted yet for this study

Summary

To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.

Conditions

  • Colorectal Neoplasms Malignant

Interventions

DRUG

Irinotecan liposome (ll) + 5-FU/LV + bevacizumab

1. Bevacizumab: 5 mg/kg, d1, q2w; 2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w; 3. leucovorin: 400 mg/m2, d1, q2w; 4. 5-fluorouracil: 2800 mg/m2, d1, q2w.

Sponsors & Collaborators

  • Affiliated Hospital of Nantong University

    lead OTHER

Principal Investigators

  • Qiang Q Xue · Affiliated Hospital of Nantong University

  • Youlang Y Zhou · Affiliated Hospital of Nantong University

  • Feiran F Wang · Affiliated Hospital of Nantong University

  • Huajie H Miu · Affiliated Hospital of Nantong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-04
Primary Completion
2026-10-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643793 on ClinicalTrials.gov